Research progress on molecular markers of immunosenescence in tumor development and immune checkpoint inhibitor therapy
Immune checkpoint inhibitors(ICI)have brought breakthrough advancements to cancer therapy.However,the relatively low treatment response rate remains a significant challenge,highlighting the urgent need for effective laboratory biomarkers to monitor immunotherapy.Immunosenescence promotes tumor initiation and progression by reducing the immune surveillance capability of the body and plays a critical role in tumor progression and immunotherapy.With the application of techniques such as flow cytometry,multi-omics analysis,and single-cell technology,the detection of immunosenescence molecular markers has made significant progress in tumor risk assessment,prognosis prediction,and ICI efficacy monitoring.
万方数据
维普
